Clinuvel Pharmaceuticals Limited

ASX:CUV Voorraadrapport

Marktkapitalisatie: AU$684.3m

Clinuvel Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Clinuvel Pharmaceuticals is Philippe Wolgen, benoemd in Nov2005, heeft een ambtstermijn van 19.08 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 3.74M, bestaande uit 47.2% salaris en 52.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.86% van de aandelen van het bedrijf, ter waarde A$ 46.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 5 jaar.

Belangrijke informatie

Philippe Wolgen

Algemeen directeur

AU$3.7m

Totale compensatie

Percentage CEO-salaris47.2%
Dienstverband CEO19yrs
Eigendom CEO6.9%
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur5yrs

Recente managementupdates

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Analyse CEO-vergoeding

Hoe is Philippe Wolgen's beloning veranderd ten opzichte van Clinuvel Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024AU$4mAU$2m

AU$36m

Mar 31 2024n/an/a

AU$33m

Dec 31 2023n/an/a

AU$30m

Sep 30 2023n/an/a

AU$30m

Jun 30 2023AU$6mAU$2m

AU$31m

Mar 31 2023n/an/a

AU$29m

Dec 31 2022n/an/a

AU$26m

Sep 30 2022n/an/a

AU$24m

Jun 30 2022AU$7mAU$1m

AU$21m

Mar 31 2022n/an/a

AU$22m

Dec 31 2021n/an/a

AU$24m

Sep 30 2021n/an/a

AU$24m

Jun 30 2021AU$5mAU$2m

AU$25m

Mar 31 2021n/an/a

AU$23m

Dec 31 2020n/an/a

AU$21m

Sep 30 2020n/an/a

AU$18m

Jun 30 2020AU$3mAU$2m

AU$15m

Mar 31 2020n/an/a

AU$15m

Dec 31 2019n/an/a

AU$15m

Sep 30 2019n/an/a

AU$16m

Jun 30 2019AU$1mAU$894k

AU$18m

Mar 31 2019n/an/a

AU$17m

Dec 31 2018n/an/a

AU$16m

Sep 30 2018n/an/a

AU$15m

Jun 30 2018AU$2mAU$818k

AU$13m

Compensatie versus markt: De totale vergoeding ($USD 2.48M ) Philippe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 922.49K ).

Compensatie versus inkomsten: De vergoeding van Philippe is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Philippe Wolgen (61 yo)

19yrs

Tenure

AU$3,742,412

Compensatie

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Philippe Wolgen
CEO, MD & Director19yrsAU$3.74m6.86%
A$ 46.9m
Dennis Wright
Chief Scientific Officer12.2yrsAU$782.61k0.38%
A$ 2.6m
Peter Vaughan
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Lachlan Hay
Chief Operations Officerno datageen gegevensgeen gegevens
Malcolm Bull
Head of Australian Operations & Investor Relationsno datageen gegevensgeen gegevens
Rose Quadbeck-Diel
Senior Vice President of Regulatory Affairsless than a yeargeen gegevensgeen gegevens
Azza Hamila
Head of Quality Assurance & Drug Safetyless than a yeargeen gegevensgeen gegevens
Claire Newstead-Sinclair
Company Secretaryless than a yeargeen gegevensgeen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van CUV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Philippe Wolgen
CEO, MD & Director19.1yrsAU$3.74m6.86%
A$ 46.9m
Pearl Grimes
Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Matthew Pringle
Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Susan Smith
Non-Executive Director5.2yrsAU$80.00k0.00084%
A$ 5.7k
Jeffrey Rosenfeld
Non-Executive Chairman5yrsAU$91.67k0.0063%
A$ 43.1k
Karen Agersborg
Non-Executive Director6.8yrsAU$75.00k0.028%
A$ 189.5k
Guy van Dievoet
Non-Executive Directorless than a yeargeen gegevensgeen gegevens

5.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van CUV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).